Abstract
Rationale
Methylphenidate (Ritalin) and d-amphetamine (Dexedrine), stimulants commonly prescribed for behavioral problems associated with atttention deficit hyperactivity disorder (ADHD), produce a similar constellation of behavioral effects. The results of previous studies suggest that d-amphetamine increases rates of smoking and the reinforcing effects of smoking. The effects of methylphenidate on smoking have not been assessed although it is the most commonly prescribed pharmacotherapy for ADHD and individuals with ADHD are at increased risk for smoking.
Objective
In this experiment the acute effects of a range of doses of methylphenidate (5, 10, 20, and 40 mg) and placebo were assessed in ten cigarette smokers who were not attempting to quit and were without ADHD or other Axis I psychiatric disorders.
Methods
Each dose of methylphenidate was tested once, whereas placebo was tested twice. One hour after ingesting drug, participants were allowed to smoke ad libitum for 4 h. Measures of smoking included total cigarettes smoked, total puffs, latency to the first cigarette, and carbon monoxide levels. Snacks and decaffeinated drinks were available ad libitum, and caloric intake during the 4-h smoking session was calculated.
Results
Methylphenidate dose dependently increased the total number of cigarettes smoked, number of puffs, and carbon monoxide levels. As expected, methylphenidate dose dependently decreased the number of food items consumed and caloric intake.
Conclusions
The results of this experiment suggest that methylphenidate, like d-amphetamine, increases rates of cigarette smoking.
Similar content being viewed by others
Abbreviations
- ADHD:
-
Attention Deficit Hyperactivity Disorder
- ANOVA:
-
analysis of variance
- THC:
-
Tetrahydrocannibinol
- DVD:
-
digital video disc
- CO:
-
carbon monoxide
References
Batra V, Patkar AA, Berrettini WH, Weinstein SP, Leone FT (2003) The genetic determinants of smoking. Chest 123:1730–1739
Benowitz NL (1992) Cigarette smoking and nicotine addiction. Med Clin North Am 76:415–437
Benowitz NL (1999) Nicotine addiction. Prim Care 26:611–631
Berridge KC (1996) Food reward: brain substrates of wanting and liking. Neurosci Biobehav Rev 20:1–25
Biederman J, Wilens T, Mick E, Spencer T, Faraone SV (1999) Pharmacotherapy of attention-deficit/hyperactivity disorder reduces risk for substance use disorder. Pediatrics 104:e20
Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699–711
Center for Disease Control (CDC) (2003) Annual smoking-attributable mortality, years of potential life lost, and economic costs—United States, 1995–1999. Morb Mort Wkly Rep 51:300–303
Chait LD, Griffiths RR (1983) Effects of caffeine on cigarette smoking and subjective response. Clin Pharmacol Ther 34:612–622
Cousins MS, Stamat HM, de Wit H (2001) Acute doses of d-amphetamine and bupropion increase cigarette smoking. Psychopharmacology (Berl) 157:243–253
Drug Enforcement Administration (2004) Statement by Terrance Woodworth, deputy director, office of diversion control, drug enforcement administration, before the committee on education and the workforce: subcommittee on early childhood, youth and families. http://www.dea.gov/pubs/cngrtest/ct051600.htm
Gehlert DR, Schober DA, Hemrick-Luecke SK, Krushinski J, Howbert JJ, Robertson DW, Fuller RW, Wong DT (1995) Novel halogenated analogs of tomoxetine that are potent and selective inhibitors of norepinephrine uptake in brain. Neurochem Int 26:47–52
Gerasimov MR, Franceschi M, Volkow ND, Rice O, Schiffer WK, Dewey SL (2000) Synergistic interactions between nicotine and cocaine or methylphenidate depend on the dose of dopamine transporter inhibitor. Synapse 38:432–437
Gottlieb S (2001) Methylphenidate works by increasing dopamine levels. BMJ 322:259
Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO (1991) The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. Br J Addict 86:1119–1127
Heikkila RE, Manzino L (1984) Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: specific inhibitors of dopamine uptake. Eur J Pharmacol 103:241–248
Henningfield JE (1984) Pharmacologic basis and treatment of cigarette smoking. J Clin Psychiatry 45:24–34
Henningfield JE, Griffiths RR (1981) Cigarette smoking and subjective response: effects of d-amphetamine. Clin Pharmacol Ther 30:497–505
Hoffman BB (2001) Catecholamines and sympathomimetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Limbird LE, Gilman AG (eds) Goodman & Gilman's the pharmacological basis of therapeutics. McGraw-Hill, New York, pp 215–268
Huston-Lyons D, Sarkar M, Kornetsky C (1993) Nicotine and brain-stimulation reward: interactions with morphine, amphetamine and pimozide. Pharmacol Biochem Behav 46:453–457
Interobserver Reliability (2004) http://www.ccny.cuny.edu/bbpsy/modules/interob_reliability.htm. Accessed 15 Jul 2004
Jasinski DR (2000) An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol 14:53–60
Javitch JA, Blaustein RO, Synder SH (1984) [3H] Mazindol binding associated with neuronal dopamine and norepinephrine uptake sites. Mol Pharmacol 26:35–44
Kollins SH, Rush CR, Pazzaglia PJ, Ali JA (1998) Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. Exp Clin Psychopharmacol 6:367–374
Kuczenski R, Segal DS (1997) Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem 68:2032–2037
Lage L, Hwang P (2004) Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment. J Child Adolesc Psychopharmacol 14:575–581
Lambert NM (2002) Stimulant treatment as a risk factor for nicotine use and substance abuse. In: Jensen PS, Cooper JR (eds) Attention deficit hyperactivity disorder: state of science: best practices. Civic Research Institute (CRI), Kingston, NJ, pp 18-1–18-24
Lambert NM, Hartsough CS (1998) Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J Learn Disabil 31:533–544
Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH (2000) Smoking and mental illness: a population-based prevalence study. JAMA 284:2606–2610
Leddy JJ, Epstein LH, Jaroni JL, Roemmich JN, Paluch RA, Goldfield GS, Lerman C (2004) Influence of methylphenidate on eating in obese men. Obes Res 12:224–232
Leung AK, Lemay JF (2003) Attention deficit hyperactivity disorder: an update. Adv Ther 20:305–318
Li MD (2003) The genetics of smoking related behavior: a brief review. Am J Med Sci 326:168–173
Lu Y, Tong S, Oldenburg B (2001) Determinants of smoking and cessation during and after pregnancy. Health Promot Int 16:355–365
Martin WR, Sloan JW, Sapira JD, Jasinski DR (1971) Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12:245–258
Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D (2002) Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159:1896–1901
Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, Kelsey D, Wernicke J, Dietrich A, Milton D (2003) Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 53:112–120
Mignot E, Nishino S, Guilleminault C, Dement WC (1994) Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 17:436–437
Milberger S, Biederman J, Faraone SV, Chen L, Jones J (1997a) Further evidence of an association between attention-deficit/hyperactivity disorder and cigarette smoking. Findings from a high-risk sample of siblings. Am J Addict 6:205–217
Milberger S, Biederman J, Faraone SV, Wilens T, Chu MP (1997b) Associations between ADHD and psychoactive substance use disorders. Findings from a longitudinal study of high-risk siblings of ADHD children. Am J Addict 6:318–329
National Institute on Drug Abuse (NIDA) (2002) Research report series: nicotine addiction. http://www.drugabuse.gov/researchreports/nicotine/nicotine.html
National Survey on Drug Use and Health (NSDUH) (2002) Chapter 4: tobacco. http://www.oas.samhsa.gov/nhsda.2k2nsduh/Overview/2k2Overview.htm#chap4
Oliveto AH, Bickel WK, Hughes JR, Shea PJ, Higgins ST, Fenwick JW (1992) Caffeine drug discrimination in humans: acquisition, specificity and correlation with self-reports. J Pharmacol Exp Ther 261:885–894
Perkins KA (1999) Nicotine self-administration. Nicotine Tob Res 1(Suppl 2):S133–S137 (discussion S139–S140)
Pomerleau OF, Downey KK, Stelson FW, Pomerleau CS (1995) Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J Subst Abuse 7:373–378
Reeves G, Schweitzer J (2004) Pharmacological management of attention-deficit hyperactivity disorder. Expert Opin Pharmacother 5:1313–1320
Rowland AS, Lesesne CA, Abramowitz AJ (2002) The epidemiology of attention-deficit/hyperactivity disorder (ADHD): a public health view. Ment Retard Dev Disabil 8:162–170
Rugino TA, Copley TC (2001) Effects of modafinil in children with attention-deficit/hyperactivity disorder: an open-label study. J Am Acad Child Adolesc Psychiatry 40:230–235
Rugino TA, Samsock TC (2003) Modafinil in children with attention-deficit hyperactivity disorder. Pediatr Neurol 29:136–142
Rush CR, Baker RW (2001) Behavioral pharmacological similarities between methylphenidate and cocaine in cocaine abusers. Exp Clin Psychopharmacol 9:59–73
Rush CR, Kollins SH, Pazzaglia PJ (1998) Discriminative-stimulus and participant-rated effects of methylphenidate, bupropion and triazolam in d-amphetamine-trained humans. Exp Clin Psychopharmacol 6:32–44
Rush CR, Essman WD, Simpson CA, Baker RW (2001) Reinforcing and subject-rated effects of methylphenidate and d-amphetamine in non-drug-abusing volunteers. J Clin Psychopharmacol 21:273–286
Rush CR, Stoops WW, Hays LR, Glaser PEA, Hays LS (2003) Risperidone attenuates the discriminative-stimulus of d-amphetamine in humans. J Pharmacol Exp Ther 306:195–204
Scahill L, Schwab-Stone M (2000) Epidemiology of ADHD in school-age children. Child Adolesc Psychiatr Clin N Am 9:541–555 (vii)
Schuster CR, Lucchesi BR, Emley GS (1979) The effects of d-amphetamine, meprobamate, and lobeline on the cigarette smoking behavior of normal human subjects. NIDA Res Monogr 23:91–99
Sigmon SC, Tidey JW, Badger GJ, Higgins ST (2003) Acute effects of D-amphetamine on progressive-ratio performance maintained by cigarette smoking and money. Psychopharmacology (Berl) 167:393–402
Simpson D, Plosker GL (2004) Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs 64:205–222
Spencer TJ, Biederman J, Wilens TE, Faraone SV (2002) Novel treatments for attention-deficit/hyperactivity disorder in children. J Clin Psychiatry 63(Suppl 12):16–22
Spencer T, Biederman J, Wilens T (2004) Stimulant treatment of adult attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 27:361–372
Stellman SD, Resnicow K (1997) Tobacco smoking, cancer and social class. IARC Sci Publ 138:229–250
Stoops WW, Fillmore MT, Glaser PEA, Rush CR (2004) Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans. J Psychopharmacol 18:534–543
Stoops WW, Lile JA, Fillmore MT, Glaser PEA, Rush CR (2005a) Reinforcing effects of methylphenidate: influence of dose and environmental demands following drug administration. Psychopharmacology 177:349–355
Stoops WW, Lile JA, Glaser PEA, Rush CR (2005b) Discriminative-stimulus and self-reported effects of methylphenidate, d-amphetamine, and triazolam in methylphenidate-trained humans. Exp Clin Psychopharmacol 13:56–64
Szatmari P (1992) The epidemiology of attention-deficit hyperactive disorder. Child Adolesc Psychiatr Clin N Am 1:361–384
Taylor FB, Russo J (2000) Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol 10:311–320
Tercyak KP, Lerman C, Audrain J (2002) Association of attention-deficit/hyperactivity disorder symptoms with levels of cigarette smoking in a community sample of adolescents. J Am Acad Child Adolesc Psychiatry 41:799–805
Tidey JW, O'Neill SC, Higgins ST (2000) d-Amphetamine increases choice of cigarette smoking over monetary reinforcement. Psychopharmacology (Berl) 153:85–92
Tyas SL, Pederson LL (1998) Psychosocial factors related to adolescent smoking: a critical review of the literature. Tob Control 7:409–420
Tyndale RF (2003) Genetics of alcohol and tobacco use in humans. Ann Med 35:94–121
Volkow ND, Wang G, Fowler JS, Logan J, Gerasimov M, Maynard L, Ding Y, Gatley SJ, Gifford A, Franceschi D (2001) Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 21:RC121
Whalen CK, Jamner LD, Hnker B, Gehricke JG, King PS (2003) Is there a link between adolescent cigarette smoking and pharmacotherapy for ADHD? Psychol Addict Behav 17:332–335
Yoshimasu K, Kiyohara C (2003) Genetic influences on smoking behavior and nicotine dependence: a review. J Epidemiol 13:183–192
Acknowledgements
The authors wish to thank Frances P. Wagner, R.N., for her expert nursing assistance and Thomas E. Wooters and Angela J. Owens for their expert technical assistance. The National Institute on Drug Abuse grant DA 012665 (C.R.R.) supported this research.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rush, C.R., Higgins, S.T., Vansickel, A.R. et al. Methylphenidate increases cigarette smoking. Psychopharmacology 181, 781–789 (2005). https://doi.org/10.1007/s00213-005-0021-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-005-0021-8